4.7 Article

Effect of Aspirin on Activities of Daily Living Disability in Community-Dwelling Older Adults

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/gerona/glaa316

Keywords

Aspirin; Clinical trials; Functional performance; Physical function; Preventive health care

Funding

  1. National Institute on Aging
  2. National Cancer Institute at the National Institutes of Health [U01AG029824]
  3. National Health and Medical Research Council (NHMRC) of Australia [334047, 1127060]
  4. Monash University
  5. NHMRC Dementia Research Leader Fellowship [APP1135727]
  6. NHMRC Principal Research Fellowship [APP1136372]
  7. Victorian Cancer Agency

Ask authors/readers for more resources

In initially healthy older adults, low-dose aspirin did not reduce the risk of incident activities of daily living (ADL) disability, but showed evidence of reducing persistent ADL disability.
Background: Cerebrovascular events, dementia, and cancer can contribute to physical disability with activities of daily living (ADL). It is unclear whether low-dose aspirin reduces this burden in aging populations. In a secondary analysis, we now examine aspirin's effects on incident and persistent ADL disability within a primary prevention aspirin trial in community-dwelling older adults. Methods: The ASPREE (ASPirin in Reducing Events in the Elderly) trial of daily 100 mg aspirin versus placebo recruited 19 114 healthy adults aged 70+ years (65+ years if U.S. minority) in Australia and the United States. Six basic ADLs were assessed every 6 months. Incident ADL disability was defined as inability or severe difficulty with >= 1 ADL; persistence was confirmed if the same ADL disability remained after 6 months. Proportional hazards modeling compared time to incident or persistent ADL disability for aspirin versus placebo; death without prior disability was a competing risk. Results: Over a median of 4.7 years, incident ADL disability was similar in those receiving aspirin (776/9525) and placebo (787/9589) with walking, bathing, dressing, and transferring the most commonly reported. Only 24% of incident ADL disability progressed to persistent. Persistent ADL disability was lower in the aspirin group (4.3 vs 5.3 events/1000 py; hazard ratio [HR] = 0.81, 95% confidence interval [CI]: 0.66-1.00), with bathing and dressing the most common ADL disabilities in both groups. Following persistent ADL disability, there were more deaths in the aspirin group (24 vs 12). Discussion: Low-dose aspirin in initially healthy older people did not reduce the risk of incident ADL disability, although there was evidence of reduced persistent ADL disability.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available